

CERTIFICATE OF ANALYSIS

Customer: Advanced Compounding Solutions Accession Number 560908

Received: 01/12/2022 Storage: Room Temperature

Compound: 71546-951-10 - Midazolam 100mg/100ml NS Device/Amount: bag(s) 13 x 100 ml

injection (1mg/ml)(150ml PAB mixing container)(total volume 100ml)

Lot Code: 20220111-3A45B7 Sample Number: W-1-6169

Purchase 1 DEA: Yes

Order:

RESULTS

Test	Active	Test Spec	Test Result	Test Date	Tech Review Date	Comment
Potency/Purity : HPLC	Midazolam	90.0 - 110.0 %	100.3% (1.0 mg/mL)	01/13/2022	01/17/2022	
Endotoxin : USP <85>		≤ 8.33 EU/mL	<0.25 EU/mL	01/17/2022	01/18/2022	
Sterility : USP <71>		Negative at 14 days	Negative at 14 days	01/27/2022	01/27/2022	
Particulate Matter : USP <788> SVI		≥10um; ≤6000/container ≥25um; ≤600/container	Meets Requirements	01/14/2022	01/17/2022	≥10µm; 40.0 parts/container ≥25µm; 0.0 parts/container

Compounded By: Abraham, Ansil Date Compounded: 1/11/2022

Limited Warranty

DYNALABS, LLC, guarantees the testing services provided are performed satisfactorily for the use for which they are intended. Results on the Certificate of Analysis were generated from, and relate only to, the sample as they were received and only to the tests performed. The specifications are input by DYNALABS but approved by the client. The client selection of Sample Purpose has implications in testing processes used. It is the practitioner's responsibility to exhibit professional judgment regarding the release of any product for dispensing purposes. The liability of DYNALABS under this warranty is limited to service credit or replacement at the discretion of DYNALABS. DYNALABS shall not be responsible for incidental or consequential damages of any kind. This warranty is exclusive and in lieu of all other warranties expressed or implied. DYNALABS does not make any warranty of merchantability with respect to the products tested, and there are no other warranties extending beyond the description on the face hereof.

Final QA By: Allison Steinbrueck Date: 01/27/2022